Boundless Bio Common Stock Analysis
| BOLD Stock | USD 1.20 0.01 0.83% |
Boundless Bio Common holds a debt-to-equity ratio of 0.078. At present, Boundless Bio's Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Debt To Equity is expected to grow to 0.30, whereas Net Debt To EBITDA is projected to grow to (0.36). Boundless Bio's financial risk is the risk to Boundless Bio stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Boundless Bio's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Boundless Bio's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Boundless Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Boundless Bio's stakeholders.
For most companies, including Boundless Bio, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Boundless Bio Common, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Boundless Bio's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
At present, Boundless Bio's Non Current Liabilities Total is projected to increase significantly based on the last few years of reporting. Boundless Bio Common is undervalued with Real Value of 1.61 and Target Price of 3.0. The main objective of Boundless Bio stock analysis is to determine its intrinsic value, which is an estimate of what Boundless Bio Common is worth, separate from its market price. There are two main types of Boundless Bio's stock analysis: fundamental analysis and technical analysis.
The Boundless Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Boundless Bio's ongoing operational relationships across important fundamental and technical indicators.
Boundless | Build AI portfolio with Boundless Stock |
Boundless Stock Analysis Notes
About 58.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Boundless Bio Common recorded a loss per share of 2.66. The entity had not issued any dividends in recent years. The firm had 1:25 split on the March 31, 2011. Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California. Audentes Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. For more info on Boundless Bio Common please contact Zachary Hornby at 858 766 9912 or go to https://boundlessbio.com.Boundless Bio Common Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Boundless Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Boundless Bio Common or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Boundless Bio Common generated a negative expected return over the last 90 days | |
| Boundless Bio Common may become a speculative penny stock | |
| Boundless Bio Common has high historical volatility and very poor performance | |
| Boundless Bio Common has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (65.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Boundless Bio Common currently holds about 351.46 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Boundless Bio Common has a very weak financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: How rising interest rates impact Boundless Bio Inc. stock - July 2025 Rallies Risk Controlled Stock Alerts - ulpravda.ru |
Boundless Largest EPS Surprises
Earnings surprises can significantly impact Boundless Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-08-10 | 2017-06-30 | -0.79 | -0.87 | -0.08 | 10 | ||
2018-11-06 | 2018-09-30 | -0.88 | -0.97 | -0.09 | 10 | ||
2025-03-27 | 2024-12-31 | -0.84 | -0.74 | 0.1 | 11 |
Boundless Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.86 M.Boundless Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
Management Efficiency
Boundless Bio Common has return on total asset (ROA) of (0.2466) % which means that it has lost $0.2466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4488) %, meaning that it created substantial loss on money invested by shareholders. Boundless Bio's management efficiency ratios could be used to measure how well Boundless Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 2, 2026, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.35. At present, Boundless Bio's Debt To Assets are projected to increase slightly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.20 | 10.71 | |
| Tangible Book Value Per Share | 10.20 | 10.71 | |
| Enterprise Value Over EBITDA | (1.26) | (1.19) | |
| Price Book Value Ratio | 0.29 | 0.31 | |
| Enterprise Value Multiple | (1.26) | (1.19) | |
| Price Fair Value | 0.29 | 0.31 | |
| Enterprise Value | -19.4 M | -20.3 M |
The decision-making processes within Boundless Bio are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Technical Drivers
As of the 2nd of January, Boundless Bio shows the Downside Deviation of 3.13, mean deviation of 2.29, and Risk Adjusted Performance of 0.0186. Boundless Bio Common technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Boundless Bio Common treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if Boundless Bio Common is priced correctly, providing market reflects its regular price of 1.2 per share. Given that Boundless Bio is a hitting penny stock territory we recommend to closely look at its total risk alpha.Boundless Bio Common Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Boundless Bio Common price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Boundless Bio Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Boundless Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Boundless Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Boundless Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Boundless Bio Outstanding Bonds
Boundless Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Boundless Bio Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Boundless bonds can be classified according to their maturity, which is the date when Boundless Bio Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Boundless Bio Predictive Daily Indicators
Boundless Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Boundless Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0726 | |||
| Daily Balance Of Power | (0.11) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 1.19 | |||
| Day Typical Price | 1.2 | |||
| Market Facilitation Index | 0.09 | |||
| Period Momentum Indicator | (0.01) |
Boundless Bio Forecast Models
Boundless Bio's time-series forecasting models are one of many Boundless Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Boundless Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Boundless Bio Bond Ratings
Boundless Bio Common financial ratings play a critical role in determining how much Boundless Bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Boundless Bio's borrowing costs.| Piotroski F Score | 1 | Very Weak | View |
| Beneish M Score | (5.75) | Unlikely Manipulator | View |
Boundless Bio Common Debt to Cash Allocation
Many companies such as Boundless Bio, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Boundless Bio Common currently holds 47.63 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Boundless Bio Common has a current ratio of 12.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Boundless Bio's use of debt, we should always consider it together with its cash and equity.Boundless Bio Total Assets Over Time
Boundless Bio Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Boundless Bio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Boundless Bio Debt Ratio | 22.0 |
Boundless Bio Corporate Bonds Issued
Most Boundless bonds can be classified according to their maturity, which is the date when Boundless Bio Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boundless Short Long Term Debt Total
Short Long Term Debt Total |
|
About Boundless Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Boundless Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Boundless shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Boundless Bio. By using and applying Boundless Stock analysis, traders can create a robust methodology for identifying Boundless entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Boundless Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Boundless analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Boundless analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 3.0 | Buy | 3 | Odds |
Most Boundless analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Boundless stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Boundless Bio Common, talking to its executives and customers, or listening to Boundless conference calls.
Boundless Stock Analysis Indicators
Boundless Bio Common stock analysis indicators help investors evaluate how Boundless Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Boundless Bio shares will generate the highest return on investment. By understating and applying Boundless Bio stock analysis, traders can identify Boundless Bio position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 24.3 M | |
| Common Stock Shares Outstanding | 17 M | |
| Total Stockholder Equity | 150.6 M | |
| Total Cashflows From Investing Activities | -26.1 M | |
| Property Plant And Equipment Net | 51.4 M | |
| Cash And Short Term Investments | 152.1 M | |
| Cash | 26.6 M | |
| Accounts Payable | 1.3 M | |
| Net Debt | 21 M | |
| 50 Day M A | 1.2368 | |
| Total Current Liabilities | 8.1 M | |
| Other Operating Expenses | 73.3 M | |
| Non Current Assets Total | 52 M | |
| Non Currrent Assets Other | 659 K | |
| Stock Based Compensation | 7.5 M |
Complementary Tools for Boundless Stock analysis
When running Boundless Bio's price analysis, check to measure Boundless Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio is operating at the current time. Most of Boundless Bio's value examination focuses on studying past and present price action to predict the probability of Boundless Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio's price. Additionally, you may evaluate how the addition of Boundless Bio to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |